Novartis Spreads Cardiovascular Bets with Ionis Antisense Option Deal

Further expanding its cardiovascular pipeline, Novartis has signed an option deal with Ionis – and invested $100m into the smaller company – to license two investigational antisense drugs targeting cardiovascular indications in patients with elevated levels of lipoprotein.